Search research articles
Contact Us
Filters
Showing results (1-10 of 56) with videos related to
Page
of 6
Sort By:
Nature Reviews. Drug Discovery
|
November 1, 2014
The predictive safety testing consortium and the coalition against major diseases
Diane Stephenson, John-Michael Sauer
Experimental Biology and Medicine (Maywood, N.J.)
|
November 25, 2017
Preclinical biomarker qualification
John-Michael Sauer, Amy C Porter,
Experimental Biology and Medicine (Maywood, N.J.)
|
March 24, 2021
Qualification of translational safety biomarkers
John-Michael Sauer, Amy C Porter
Clinical Pharmacokinetics
|
May 25, 2005
Clinical pharmacokinetics of atomoxetine
John-Michael Sauer, Barbara J Ring, Jennifer W Witcher
ILAR Journal
|
January 6, 2017
Promoting Adoption of the 3Rs through Regulatory Qualification
Elizabeth Gribble Walker, Amanda F Baker, John-Michael Sauer
Toxicological Research
|
March 16, 2016
Advancing Risk Assessment through the Application of Systems Toxicology
John Michael Sauer, André Kleensang, Manuel C Peitsch, et al.
Antibiotics (Basel, Switzerland)
|
January 21, 2022
The Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections
David Huang, Nicholas Pachuda, John Michael Sauer, et al.
International Journal of Toxicology
|
March 26, 2015
Systems Toxicology: The Future of Risk Assessment
John Michael Sauer, Thomas Hartung, Marcel Leist, et al.
Toxicology
|
July 2, 2003
Species comparison of vitamin K1 2,3-epoxide reductase activity in vitro: kinetics and warfarin inhibition
Christina R Wilson, John-Michael Sauer, Gary P Carlson, et al.
Assay and Drug Development Technologies
|
June 6, 2012
Monitoring signaling by the p75(NTR) receptor utilizing a caspase-3 activation assay amenable to small-molecule screening
J Michael Bradshaw, Lan Nguyen, William Wallace, et al.
Page
of 6
Search research articles
Search
Showing results (1-10 of 56) with videos related to
Sort By:
Page
of 6
Nature Reviews. Drug Discovery
|
November 1, 2014
The predictive safety testing consortium and the coalition against major diseases
Diane Stephenson, John-Michael Sauer
Experimental Biology and Medicine (Maywood, N.J.)
|
November 25, 2017
Preclinical biomarker qualification
John-Michael Sauer, Amy C Porter,
Experimental Biology and Medicine (Maywood, N.J.)
|
March 24, 2021
Qualification of translational safety biomarkers
John-Michael Sauer, Amy C Porter
Clinical Pharmacokinetics
|
May 25, 2005
Clinical pharmacokinetics of atomoxetine
John-Michael Sauer, Barbara J Ring, Jennifer W Witcher
ILAR Journal
|
January 6, 2017
Promoting Adoption of the 3Rs through Regulatory Qualification
Elizabeth Gribble Walker, Amanda F Baker, John-Michael Sauer
Toxicological Research
|
March 16, 2016
Advancing Risk Assessment through the Application of Systems Toxicology
John Michael Sauer, André Kleensang, Manuel C Peitsch, et al.
Antibiotics (Basel, Switzerland)
|
January 21, 2022
The Engineered Antibiotic Peptide PLG0206 Eliminates Biofilms and Is a Potential Treatment for Periprosthetic Joint Infections
David Huang, Nicholas Pachuda, John Michael Sauer, et al.
International Journal of Toxicology
|
March 26, 2015
Systems Toxicology: The Future of Risk Assessment
John Michael Sauer, Thomas Hartung, Marcel Leist, et al.
Toxicology
|
July 2, 2003
Species comparison of vitamin K1 2,3-epoxide reductase activity in vitro: kinetics and warfarin inhibition
Christina R Wilson, John-Michael Sauer, Gary P Carlson, et al.
Assay and Drug Development Technologies
|
June 6, 2012
Monitoring signaling by the p75(NTR) receptor utilizing a caspase-3 activation assay amenable to small-molecule screening
J Michael Bradshaw, Lan Nguyen, William Wallace, et al.
Page
of 6